Michelle Hermiston, MD, PhD

2019 - Diversity, Equity, and Inclusion Champion Training, University of California
Residency, - Pediatrics, University of California, San Francisco
  1. Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia.
  2. Optimal fludarabine lymphodepletion is associated with improved outcomes following CAR T-cell Therapy.
  3. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
  4. Expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.
  5. A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients.
  6. Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
  7. Tisagenlecleucel Outcomes in Relapsed/Refractory Extramedullary ALL: A Pediatric Real World CAR Consortium Report.
  8. Decreased IL-10 accelerates B-cell leukemia/lymphoma in a mouse model of pediatric lymphoid leukemia.
  9. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
  10. Out of Specification Tisagenlecleucel Does Not Compromise Safety or Efficacy in Pediatric Acute Lymphoblastic Leukemia.
  11. Digenic Inheritance: Evidence and Gaps in Hemophagocytic Lymphohistiocytosis.
  12. Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from
  13. Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) in Combination with UK ALL-R3 Induction Chemotherapy for Children, Adolescents and Young Adults with Relapsed Acute Lymphoblastic Leukemia (ALL): A Therapeutic Advances in Childhood Leukemia and Lym
  14. Perceptions of specialty palliative care and its role in pediatric stem cell transplant: A multidisciplinary qualitative study.
  15. IFN-? signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS.
  16. ALL-026: Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study.
  17. Poster: ALL-026: Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study.
  18. Subcutaneous panniculitis-like T-cell lymphomas with homozygous inheritance of HAVCR2 mutations in Vietnamese pedigrees.
  19. Concurrent Subcutaneous Panniculitis-like T-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia in 2 Pediatric Patients.
  20. Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.
  21. Fludarabine-exposure predicts disease control following CD19-specific car t cell (tisagenlecleucel); a report from pediatric real-world car consortium.
  22. T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis.
  23. Double trouble for Langerhans cell histiocytosis.
  24. 149 Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study.
  25. Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL
  26. HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia.
  27. ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma.
  28. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.
  29. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
  30. Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes.
  31. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
  32. Protein Translocation Inhibitors Overcome Cytokine-Induced Glucocorticoid Resistance in T-Cell Acute Lymphoblastic Leukemia.
  33. Role of Disease Mechanism in Hematopoietic Cell Transplantation Outcomes for Hemophagocytic Lymphohistiocytosis.
  34. The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis.
  35. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO).
  36. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
  37. Calming the storm in HLH.
  39. Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.
  40. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities.
  41. Mechanisms of Glucocorticoid Response and Resistance in Lymphoid Malignancies.
  42. The bone marrow microenvironment as a mediator of chemoresistance in acute lymphoblastic leukemia.
  43. The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities.
  44. Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL).
  45. Glucocorticoids Paradoxically Induce Intrinsic Steroid Resistance through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia.
  46. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.
  47. Age-Related Impaired Efficacy of Bone Marrow Cell Therapy for Myocardial Infarction Reflects a Decrease in B Lymphocytes.
  48. High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL.
  49. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
  50. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.
  51. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas.
  52. Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.
  53. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
  54. CRLF2 Rearrangement Status in Ph-like ALL Predicts Intrinsic Glucocorticoid Resistance In Vitro that is Reversible with Targeted MAPK and PI3K Pathway Inhibition.
  55. JAK/STAT Pathway Inhibition Reverts IL7-Induced Glucocorticoid Resistance in a Subset of Human T-Cell Acute Lymphoblastic Leukemia.
  56. Measurement of Phosphorylated ERK As a Prognostic and Predictive Marker for MEK Inhibition in Pediatric B-Lymphoblastic Leukemia: A Pilot Study.
  57. Mechanism of IL-10 Protective Effect in Development of Childhood B Cell Acute Lymphoblastic Leukemia.
  58. Microrna (miR)-17-92 Contributes to Therapy Resistance in Burkitt Lymphoma Cells.
  59. Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.
  60. Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL.
  61. Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL.
  62. Abstract 17412: Paracrine Role of B Lymphocytes in Successful Bone Marrow Cell Therapy for Myocardial Infarction.
  63. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.
  64. Unbiased modifier screen reveals that signal strength determines the regulatory role murine TLR9 plays in autoantibody production.
  65. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
  66. MAPK Signaling Cascades Mediate Distinct Glucocorticoid Resistance Mechanisms in Pediatric B-Precursor ALL.
  67. The CXCR4/CXCL12 Axis Mediates Chemotaxis, Survival, and Chemoresistance in T-Cell Acute Lymphoblastic Leukemia.
  68. Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia.
  69. A(nother) RAF mutation in LCH.
  70. Histone Deacetylase Inhibitors Enhance Cell Death In Burkitt Lymphoma Cells By Modulating Expression Of The WNT/ß-Catenin Pathway and Survivin.
  71. Inhibition Of The Wnt Pathway Leads To Improved Chemosensitivity In Pediatric Acute Lymphoblastic Leukemia.
  72. Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion Of MIR17HG In Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity.
  73. The structural wedge domain of the receptor-like tyrosine phosphatase CD45 enforces B cell tolerance by regulating substrate specificity.
  74. Initially disadvantaged, TEL-AML1 cells expand and initiate leukemia in response to irradiation and cooperating mutations.
  75. The Order of Exposure to Cytotoxic Chemotherapy and the Proteasome Inhibitor Bortezomib Dictates the Extent of Reversal of Chemotherapy Resistance in T-ALL.
  76. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
  77. Aberrant MAPK and PI3K Signaling Contribute to Chemotherapy Resistance in T Cell Acute Lymphoblastic Leukemia by Altering the Balance of Apoptosis Mediators,.
  78. Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project.
  79. Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediated inflammatory response.
  80. Chapter 95 CD45.
  81. Distinct Signaling Profiles and Drug Responses Identify Subpopulations of Pediatric T-Cell Acute Lymphoblastic Leukemia and Lymphoma Patients.
  82. PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background.
  83. Requirement for CD45 in fine-tuning mast cell responses mediated by different ligand-receptor systems.
  84. Oncogenic Kras initiates leukemia in hematopoietic stem cells.
  85. CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells.
  86. Differential impact of the CD45 juxtamembrane wedge on central and peripheral T cell receptor responses.
  87. B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and Fas deficiency.
  88. Langerhans' Cell Histiocytosis.
  89. A Point Mutation in the Juxtamembrane Wedge of CD45 Impacts Myeloid Development and Generates a Novel Model for Hemophagocytic Disorders in the Context of a MHC I-Restricted Transgene.
  90. The Phenotypic Consequences of an Activating Mutation in the Juxtamembrane Wedge of CD45 Is Sensitive to Genetic Modifiers.
  91. Epstein-Barr virus-associated B cell lymphoproliferative disease in a child with neonatal-onset multisystem inflammatory disease.
  92. Dysregulation of signaling pathways in CD45-deficient NK cells leads to differentially regulated cytotoxicity and cytokine production.
  93. The juxtamembrane wedge negatively regulates CD45 function in B cells.
  94. Chapter 114 CD45.
  95. A practical approach to the evaluation of the anemic child.
  96. Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases.
  97. CD45: a critical regulator of signaling thresholds in immune cells.
  98. Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene.
  99. Forced expression of the tumor suppressor adenomatosis polyposis coli protein induces disordered cell migration in the intestinal epithelium.
  100. Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for nonautonomous regulation of cell fate in a self-renewing system.
  101. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin.
  102. Organization of the crypt-villus axis and evolution of its stem cell hierarchy during intestinal development.
  103. In vivo analysis of cadherin function in the mouse intestinal epithelium: essential roles in adhesion, maintenance of differentiation, and regulation of programmed cell death.
  104. Differentiation and self-renewal in the mouse gastrointestinal epithelium.
  105. Chimeric-transgenic mice represent a powerful tool for studying how the proliferation and differentiation programs of intestinal epithelial cell lineages are regulated.
  106. Use of transgenic mice to characterize the multipotent intestinal stem cell and to analyze regulation of gene expression in various epithelial cell lineages as a function of their position along the cephalocaudal and crypt-to-villus (or crypt-to-surface e
  107. Simultaneous localization of six antigens in single sections of transgenic mouse intestine using a combination of light and fluorescence microscopy.
  108. Use of transgenic mice to infer the biological properties of small intestinal stem cells and to examine the lineage relationships of their descendants.
  109. Isolation of mutants defective in early steps of meiotic recombination in the yeast Saccharomyces cerevisiae.